凯普生物(300639) - 2017 Q3 - 季度财报

Financial Performance - Operating revenue for the period was CNY 125,580,286.46, reflecting a year-on-year growth of 23.50%[7] - Net profit attributable to shareholders rose by 43.72% to CNY 27,602,795.58[7] - Basic earnings per share increased by 7.80% to CNY 0.3067[7] - Total operating revenue for the current period reached ¥125,580,286.46, an increase of 23.5% compared to ¥101,680,664.14 in the previous period[36] - Total operating costs amounted to ¥96,988,140.38, up from ¥79,820,931.99, reflecting a growth of 21.5%[36] - Operating profit for the current period was ¥33,220,755.64, representing a 52.2% increase from ¥21,859,732.15 in the previous period[37] - Net profit attributable to shareholders was ¥27,602,795.58, a rise of 43.8% compared to ¥19,205,663.20 in the previous period[38] - Total comprehensive income for the current period was ¥27,855,595.96, compared to ¥18,609,461.18 in the previous period, indicating a growth of 49.5%[38] Assets and Liabilities - Total assets reached CNY 1,024,568,863.10, an increase of 76.91% compared to the previous year[7] - Total current assets increased significantly from CNY 248,908,784.78 to CNY 665,664,276.53, representing a growth of approximately 167%[28] - Total non-current assets grew from CNY 330,242,766.41 to CNY 358,904,586.57, an increase of about 8.5%[29] - Total liabilities increased from CNY 77,486,547.07 to CNY 85,788,822.44, which is an increase of about 10%[30] - The company’s total liabilities and equity reached CNY 1,024,568,863.10, up from CNY 579,151,551.19, indicating a total growth of about 77%[31] Shareholder Information - The total number of shareholders at the end of the reporting period was 12,182[11] - The largest shareholder, Hong Kong Science and Technology Venture Capital Co., Ltd., held 32.33% of the shares[11] - The equity attributable to the parent company rose from CNY 489,489,313.01 to CNY 929,216,167.08, representing an increase of approximately 90%[31] Cash Flow - The company reported a net cash flow from operating activities of CNY 37,575,937.09, up 70.70% year-to-date[7] - Cash flow from operating activities generated a net amount of CNY 37,575,937.09, significantly higher than CNY 22,013,230.59 in the same period last year, representing an increase of approximately 70.9%[52] - The net cash flow from financing activities was 387,072,828.03 CNY, significantly higher than 9,289,458.35 CNY in the previous period[55] - The total cash and cash equivalents at the end of the period reached 96,428,626.97 CNY, compared to 16,102,793.23 CNY at the end of the previous period[55] Operational Developments - The company implemented a restricted stock incentive plan, granting a total of 1,017,000 shares to 213 incentive objects[19] - The company successfully won bids for HPV testing in Zhejiang Province, becoming the only manufacturer to win in both categories of the tender[19] - The company approved the establishment of two wholly-owned subsidiaries, Guangzhou Kaijian Precision Medical Technology Service Co., Ltd. and Guangzhou Tiancheng Medical Equipment Co., Ltd.[20] Other Income and Expenses - Non-recurring gains and losses totaled CNY 3,814,175.21 for the year-to-date period[8] - Other income increased by 100% compared to the previous period, attributed to government subsidies related to daily operations[17] - Sales expenses rose to ¥47,915,048.06 from ¥39,777,696.80, an increase of 20.4%[37] - Management expenses increased to ¥27,553,229.07 from ¥22,133,668.18, reflecting a growth of 24.4%[37]